CRISPR-engineered T cells in patients with refractory cancer
2020 · Science · 1,396 citations
https://doi.org/10.1126/science.aba7365
Y
Yangbing Zhao
Duke University(US)
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
96
Papers
14.2K
Citations
47
h-index
60
i10-index
Yangbing Zhao is an academic researcher from Duke University. The author has contributed to research in topics: CAR-T cell therapy research & Virus-based gene therapy research & Immunotherapy and Immune Responses. The author has an h-index of 47, co-authored 82 publications.
ORCID: 0000-0003-3041-2535Papers by this author
worksMultiplex Genome Editing to Generate Universal CAR T Cells Resistant to PD1 Inhibition
2016 · Clinical Cancer Research · 912 citations
https://doi.org/10.1158/1078-0432.ccr-16-1300
Mesothelin-Specific Chimeric Antigen Receptor mRNA-Engineered T Cells Induce Antitumor Activity in Solid Malignancies
2013 · Cancer Immunology Research · 847 citations
https://doi.org/10.1158/2326-6066.cir-13-0170
Affinity-Tuned ErbB2 or EGFR Chimeric Antigen Receptor T Cells Exhibit an Increased Therapeutic Index against Tumors in Mice
2015 · Cancer Research · 556 citations
https://doi.org/10.1158/0008-5472.can-15-0159
Augmentation of Antitumor Immunity by Human and Mouse CAR T Cells Secreting IL-18
2017 · Cell Reports · 483 citations
https://doi.org/10.1016/j.celrep.2017.09.002
Safety and Efficacy of Intratumoral Injections of Chimeric Antigen Receptor (CAR) T Cells in Metastatic Breast Cancer
2017 · Cancer Immunology Research · 435 citations
https://doi.org/10.1158/2326-6066.cir-17-0189
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat